Navigation Links
Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy'
Date:9/2/2008

NEW ROCHELLE, N.Y., Sept. 2 /PRNewswire/ -- The many recent reports documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in animal models of human disease may actually be describing non-specific therapeutic effects related to the ability of siRNA to activate an immune response, according to a paper in the September 2008 issue (Volume 19, Number 9) of 'Human Gene Therapy,' a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper, which was published "instant online," is available free online at http://www.liebertpub.com/hum

Marjorie Robbins, Adam Judge, Ellen Ambegia, Catherine Choi, Ed Yaworski, Lorne Palmer, Kevin McClintock, and Ian MacLachaln of Protiva Biotherapeutics (Burnaby, BC Canada), in a paper entitled, "Misinterpreting the Therapeutic Effects of siRNA Caused by Immune Stimulation," emphasize the need for researchers to design siRNA studies that incorporate suitable controls to differentiate the disease-modulating effect of an siRNA from its ability to stimulate an innate immune response.

siRNAs have been highly touted for their ability to target very specifically and selectively the disease-causing factors in a range of disorders, from viral infections to tumors and inflammatory and immunologic processes. However, siRNA also has the potential to activate innate immunity and the production of interferons, which can in turn bring about therapeutic effects in a range of disease models.

The authors of this paper contend that, "Surprisingly few of the reported studies have adequately tested, or controlled, for the potential effects of siRNA-mediated immune stimulation."

In the current study, use of a commonly used control siRNA sequence called GFP siRNA, which has only a minimal capacity to activate the immune system, clearly showed the striking difference between the immunostimulatory potential of GFP siRNA and of some other siRNAs. Us
'/>"/>

SOURCE Mary Ann Liebert, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
2. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
3. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
4. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
5. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
8. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
9. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
10. Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... several clinical studies evaluating potential new medicines in ... the upcoming 2014 European Society of Medical Oncology ... Madrid, Spain . Data being presented include ... safety and efficacy of veliparib (ABT-888), a poly ...
(Date:9/22/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today ... overview and update at the NewsMakers in the Biotech ... a.m. Eastern Time (8:30 a.m. Pacific Time), at the ... . A live audio webcast of ... section of Arena,s website at www.arenapharm.com . A ...
(Date:9/22/2014)... , September 22, 2014 ... "Cell Line Development Market by Product (Equipment, Media and ... Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, ... 2019", published by MarketsandMarkets, analyzes and studies the ... Browse 114 market data tables and ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... Dec. 7 Access Pharmaceuticals, Inc.,(OTC Bulletin ... demonstrated the,ability, using the company,s proprietary Cobalamin(TM) ... animal model of diabetes, through,its oral insulin ... based upon the body,s natural absorption of ...
... DENVER, Dec. 6 Some 5,000 COPD patients ... Antitrypsin Deficiency (Alpha-1) in,a study marking a major ... Association for Respiratory Care (AARC)., The principal ... the,Division of Pulmonary Medicine, National Jewish Medical and ...
Cached Medicine Technology:Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin 2Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin 3Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3
(Date:9/22/2014)... 22, 2014) McMaster scientists have found that an ... of antibiotics. , Although dozens of antibiotics target ... a certain part of bacteria are created, and they ... , The discovery is important as there is growing ... cures for infections ineffective. The World Health Organization has ...
(Date:9/22/2014)... 2014 Quincy Bioscience, one of ... promotes National Self-Improvement Month this September. ... should have access to self-improvement resources, especially for ... demand for products that preserve health is growing ... For over six years, Quincy Bioscience has been ...
(Date:9/22/2014)... (HealthDay News) -- Scans of young children,s brains ... This finding could potentially allow doctors to identify ... on, preliminary research suggests. "Early identification and ... as well as most neurodevelopmental disorders," the study,s ... of child and adolescent psychiatry at University of ...
(Date:9/22/2014)... September 22, 2014 In a continued ... Jeep Dodge Ram is launching an awareness campaign inspired ... (#blindeggchallenge or #ffbBEC) aims to raise awareness and funds ... throwing an egg in the air and trying to ... others and if a nominee does not complete the ...
(Date:9/22/2014)... 22, 2014 The struggles that lie ... (LEP) patients has been well-documented—reportedly, language barriers between doctors ... to the emergency room and an increased likelihood for ... At Sanford Health, the largest medical facility in the ... LEP population necessitated the need for Video Remote ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 3Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 4
... Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel will be conducting a ... 11:30 am Eastern Time. , , Event: ... Dan Starck, President and CEO, ... 11:30 am Eastern Time, Tuesday, February 3rd, ...
... success rate is much lower for those over 40 who want ... Women under 35 who undergo six cycles of in vitro fertilization ... new study found. , But for women over 40, the odds ... , "IVF is a mainstay of the treatment of infertility, and ...
... 14 ISP and IT partner Spiderhost ... initiative by Get Healthy Florida to get ... most comprehensive community-wide health project to date: a year-long ... awareness of blood pressure and cardiovascular risk.The project challenges ...
... 14 Congressman Chaka Fattah (D-PA) issues the ... the SCHIP children,s insurance program by a bipartisan vote of ... , "The effort to bring change to Washington ... children took a major stride today. I have joined with ...
... RIVER EDGE, N.J., Jan. 14 Nephros, Inc. ... company developing and marketing filtration products for therapeutic ... that it has received notice from the NYSE ... or "AMEX" or the "Exchange"), regarding AMEX,s intention ...
... still share outcome disparities in treatment of liver disease, study ... treatment for hepatitis C does not appear to help Hispanic ... non-Hispanic whites, a new study suggests. , This is second ... not to respond well to the therapy, consisting of pegylated ...
Cached Medicine News:Health News:CorVel Corporation Announces Earnings Release Webcast 2Health News:IVF Treatments Often Work for Women Under 35 2Health News:IVF Treatments Often Work for Women Under 35 3Health News:Spiderhost's Custom Programming Helps Central Floridians Get Healthy 2Health News:Nephros Receives Notice of Intention to Delist from AMEX 2Health News:Nephros Receives Notice of Intention to Delist from AMEX 3Health News:Nephros Receives Notice of Intention to Delist from AMEX 4Health News:Hispanics Respond Poorly to Standard Hepatitis C Therapy 2
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
... BTF-111 miniature arrayed detector ... spectrometer for ?uorescence applications ... excitation light source modules ... 2D ?uorescence measurement which ...
Inquire...
FlexStationII offers the highest level of flexibility in developing functional cellular assays and analyzing real time kinetic data....
Medicine Products: